Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses | Zendy

Daria V. Voronina | Zendy; Dmitry V. Shcheblyakov | Zendy; I. B. Esmagambetov | Zendy; Artem A. Derkaev | Zendy; Olga Popova | Zendy; Dmitry N. Shcherbinin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses

Author(s) -

Daria V. Voronina,

Dmitry V. Shcheblyakov,

I. B. Esmagambetov,

Artem A. Derkaev,

Olga Popova,

Dmitry N. Shcherbinin

Publication year - 2021

Publication title -

acta naturae

Language(s) - English

Resource type - Journals

ISSN - 2075-8243

DOI - 10.32607/actanaturae.11495

Subject(s) - hemagglutinin (influenza) , virology , virus , influenza a virus , biology , neutralization , phage display , antibody , influenza a virus subtype h5n1 , microbiology and biotechnology , immunology

The influenza virus infection claims ~650,000 lives annually. Taking into account the evolving resistance of the pathogen to antiviral drugs and the waning effectiveness of vaccination among certain populations, new approaches to the treatment of influenza are needed. The current study is aimed at obtaining single-domain antibodies (Nanobodies) to the highly conserved stem domain of influenza A virus hemagglutinin by phage display. Two high-affinity neutralizing clones of Nanobodies with a particular specificity were selected; they ensured 100% neutralization of the H1N1 and H5N2 influenza viruses in vivo. The obtained data demonstrate that it is possible to develop highly effective VHH-based drugs for the treatment of influenza.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research